Once a strategy has been agreed, Stravencon rigorously screens and recommends an appropriate partner from its proprietary database of the top Chinese drug manufacturers. 

Recommendation criteria will include an appropriate mix of:

• Existing EU cGMP accreditation for contract or OEM supply. 
• Audited facilities that should be approvable according to EU quality standards. 
• Regulatory management capabilities for clients requiring product registration and SFDA approvals in China.
• Access to Distribution channels to target market segments in China.

Stravencon then introduces the client to the prospective partner and assists with negotiations.